ABRAHAM KORNBERG, M.D.; RIVKA YONA, M.D.; SANDA IUKLEA, M.D.; SUZANA KAUFMAN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The successful treatment with danazol of three patients with myelodysplastic syndromes and severe thrombocytopenia was described recently by Cines and coworkers (1). After administration of danazol, the platelet count of each patient rose and clinical bleeding stopped. We have had a similar experience with one patient.
During 1985 we treated seven patients with myelodysplastic syndromes with danazol, 600 mg/d, for 2 to 4 months. Hemoglobin levels were 5 to 10.1 g/dL, leukocyte counts were 1500 to 6400/mm3, and platelet counts were 14 000 to 132 000/mm3. Previous treatment with oxymetholone, nandrolone phenpropionate, folic acid, pyridoxine phosphate, and
KORNBERG A, YONA R, IUKLEA S, et al. Danazol and Myelodysplasic Syndromes. Ann Intern Med. 1986;104:445–446. doi: https://doi.org/10.7326/0003-4819-104-3-445_3
Download citation file:
Published: Ann Intern Med. 1986;104(3):445-446.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use